Assessing Protein Expression in Patient-Derived Xenografts Using Western Blotting.

Autor:	Rossi Herling B; Drug Delivery Disposition & Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia. bruna.herling@monash.edu., Chen MZ; Drug Delivery Disposition & Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia., McLeod VM; Drug Delivery Disposition & Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Jazyk:	angličtina
Zdroj:	Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2024; Vol. 2806, pp. 209-218.
DOI:	10.1007/978-1-0716-3858-3_15
Abstrakt:	The use of patient-derived xenografts (PDXs) in cancer research is increasing due to their ability to closely mimic the features of patient tumors. The ability to quickly and robustly measure protein expression levels in these tissues is a key methodology required in a broad range of experimental designs. Western blotting (WB) is a cost effective and simple tool that is highly specific and sensitive for detecting and quantifying individual proteins, posttranslational modifications and aberrant signaling pathways. Here, we described a method to assess protein expression in PDX tissues using WB to detect proteins involved in cell growth signaling pathways. (© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu